GHRP-2 (Peptide): The Potent GH Secretagogue, Pituitary Activator, Tissue Repair Peptide

GHRP-2 is a synthetic growth hormone releasing peptide that potently and directly stimulates the pituitary gland to release growth hormone, with emerging evidence of tissue regenerative properties extending far beyond its approved use, including applications in tendon healing and diagnostic testing for adrenal function.

---

1. Overview:

GHRP-2, known formally as Pralmorelin, is a synthetic hexapeptide and a potent agonist of the growth hormone secretagogue receptor (GHSR) . While its primary clinical application is the diagnosis and treatment of growth hormone deficiency, it operates through a mechanism distinct from GHRH. It acts directly on the pituitary and hypothalamus, triggering a robust release of growth hormone. Additionally, research has revealed its ability to stimulate ACTH and cortisol release, leading to its diagnostic use in assessing adrenal axis function.

---

2. Origin & Common Forms:

GHRP-2 is a wholly synthetic peptide. It is not found in nature. It is produced via solid-phase peptide synthesis and is available as the acetate salt for pharmaceutical and research use.

---

3. Common Supplemental Forms: Standard & Enhanced

· Pralmorelin (Generic/Pharmaceutical Grade): The standard injectable form used in clinical settings for diagnostic testing (e.g., GHRP-2 stimulation test) and approved therapeutic use. It is available in vials as a lyophilized powder for reconstitution.

· Research Liquids/Powders: This peptide is also widely available from chemical supply companies for research purposes only, sold as lyophilized powder or pre-mixed sterile solutions.

---

4. Natural Origin:

· Synthetic Origin: GHRP-2 is a man-made peptide. It was developed through medicinal chemistry to mimic the activity of the natural hormone ghrelin at the GHSR receptor.

· Precursors: It is synthesized from standard and unnatural amino acids.

---

5. Synthetic / Man-made:

· Process: GHRP-2 is produced via solid-phase peptide synthesis (SPPS). This automated chemical process sequentially adds amino acids to a growing peptide chain. The sequence is: D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide .

---

6. Commercial Production:

· Precursors: Protected amino acids (Fmoc/t-Boc chemistry) and coupling reagents.

· Process: Stepwise synthesis on a resin, followed by cleavage, purification via High-Performance Liquid Chromatography (HPLC) to achieve >99% purity, and lyophilization to a powder.

· Purity & Efficacy: Pharmaceutical GHRP-2 is held to high purity standards. Its efficacy is measured by its ability to elevate plasma growth hormone levels following injection.

---

7. Key Considerations:

The Non-GHRH Pathway. GHRP-2 bypasses the traditional GHRH receptor. Instead, it targets the Ghrelin receptor (GHSR-1a) . While GHRH stimulates GH release via the cAMP/PKA pathway, GHRP-2 primarily acts via the phospholipase C (PLC) and protein kinase C (PKC) pathways . This synergistic interaction means GHRP-2 can amplify the effects of GHRH, leading to a more robust GH pulse than either alone.

---

8. Structural Similarity:

A hexapeptide (6 amino acids) with a molecular weight of 817.97 g/mol . It features a naphthylalanine residue and a D-arginine (or D-lysine in some analogs) at the C-terminus, which are critical for its high binding affinity to the GHSR receptor.

---

9. Biofriendliness:

· Utilization: Administered intravenously (clinical settings) or subcutaneously. It is stable in plasma for a short duration following administration.

· Metabolism: Degraded by proteolytic enzymes into smaller peptides and amino acids.

· Toxicity: For research use, it is classified as non-hazardous under normal handling conditions, though standard lab safety precautions apply .

---

10. Known Benefits (Clinically Supported):

· Diagnosis of Growth Hormone Deficiency: Approved for use as a diagnostic agent to assess GH secretory reserve in adults and children.

· Diagnosis of Adrenal Insufficiency: The GHRP-2 stimulation test demonstrates high sensitivity and specificity for detecting secondary hypoadrenalism (HPA axis failure), with a peak cortisol cutoff of 11.6 µg/dL providing 88.9% specificity and 89.7% sensitivity .

· Treatment of Growth Disorders: Used therapeutically in Japan for growth retardation.

· Tendon-Bone Healing (Preclinical): In a rat rotator cuff model, GHRP-2 significantly improved histologic scores, bone mineral density, and biomechanical properties (maximal failure load, stiffness) .

· Modulation of Inflammation: Shown to inhibit M1 macrophage polarization (reducing Cd86, Nos2, and tnfa expression), suggesting an anti-inflammatory mechanism distinct from its endocrine effects .

---

11. Purported Mechanisms:

· GHSR Agonism: Binds to the Ghrelin receptor (GHSR) in the hypothalamus and pituitary .

· Growth Hormone Release: Triggers GH secretion via the PKC and PLC pathways. It is more potent than GHRP-6 .

· ACTH & Cortisol Stimulation: Directly stimulates ACTH secretion in the anterior pituitary via both PKA and PKC pathways .

· Anti-Catabolic: Directly acts on myocytes to suppress muscle-specific ubiquitin ligases (Atrogin-1 and MuRF1), potentially preventing muscle breakdown (atrophy) during stress .

---

12. Other Possible Benefits Under Research:

· Rotator Cuff Repair: Identified as a transitional therapeutic candidate to enhance healing and reduce retear rates after surgery .

· Hair Growth: Limited studies suggest GHRPs may affect hair follicle cycling due to growth hormone release.

· Cardioprotection: GH secretagogues have been investigated for potential benefits in heart failure models.

---

13. Side Effects:

· Minor & Transient: Injection site reactions (pain, redness), transient flushing, headache, and nausea .

· To Be Cautious About: Hyperprolactinemia (transient rise in prolactin) and increased appetite. Long-term use requires monitoring of fasting blood glucose as GH antagonizes insulin action.

· Contraindications: Active malignancy, pregnancy/lactation, and hypersensitivity .

---

14. Dosing & How to Take:

· Diagnostic Use (Stimulation Test): Administered intravenously (bolus) at a dose of 0.5-1 mcg/kg or a standard 100mcg dose, with blood draws taken at 0, 30, 60, and 90 minutes to measure GH and cortisol.

· Research Use: Doses vary widely based on study protocol (e.g., in rat studies, a 0.1 µM concentration was used in vitro) .

· How to Take: By subcutaneous or intravenous injection only. It is degraded by stomach acid and cannot be taken orally.

---

15. Tips to Optimize Benefits:

· Clinical Setting: If undergoing testing for AGHD, fasting status is typically required for accurate baseline readings.

· Cycling (Research): Due to the risk of pituitary desensitization and antibody formation with long-term daily use, research protocols often employ cycling or pulsatile delivery strategies.

---

16. Not to Exceed / Warning / Interactions:

· Drug Interactions: Glucocorticoids may blunt the GH response. Antidiabetic medications may require dose adjustments due to the anti-insulin effects of elevated GH .

· Medical Warnings: Should not be used in patients with active cancer, as GH is a mitogen. Use with caution in patients with diabetes or diabetic retinopathy.

---

17. LD50 & Safety:

· Acute Toxicity (LD50): Not well established for humans, but classified as non-hazardous for laboratory handling .

· Human Safety: Generally safe under medical supervision for diagnostic purposes. Long-term safety for non-approved indications is not established.

---

18. Consumer Guidance:

· Label Literacy: In research settings, it is sold strictly "For Research Use Only" (RUO) . Pharmaceutical grade is Pralmorelin.

· Quality Assurance: For research, verify the Certificate of Analysis (COA) confirming peptide purity (>98%) by HPLC and mass spectrometry.

· Manage Expectations: As a potent hormone secretagogue, its effects are specific to GH pathways. The recent research on tendon healing is promising but represents early-stage (preclinical) data, not yet standard care.